\u200bWe continue to call on the Government of Zimbabwe to investigate all allegations of human rights violations and urge them to follow the due process of law for all those arrested in connection to January's protests. The British Embassy in Harare regularly raise the rights of protestors in their meetings with the Government of Zimbabwe.<\/p>
I summoned the Zimbabwean Ambassador on 17 January to urge the security forces to stop using disproportionate force and reinforce the right of the people of Zimbabwe to protest. On 30 January, I spoke to Zimbabwean Foreign Minister Moyo, repeating our calls for an end to human rights abuses and a full investigation into all alleged abuse, including arbitrary arrests.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4107", "label" : {"_value" : "Biography information for Dame Harriett Baldwin"} } , "answeringMemberConstituency" : {"_value" : "West Worcestershire"} , "answeringMemberPrinted" : {"_value" : "Harriett Baldwin"} , "dateOfAnswer" : {"_value" : "2019-03-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-03-06T16:25:09.107Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "16"} , "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"} , "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"} , "date" : {"_value" : "2019-02-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Zimbabwe: Demonstrations"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Foreign and Commonwealth Affairs, what representations he is making to the Zimbabwean Government on respecting the rights of protesters.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/320", "label" : {"_value" : "Biography information for Mr Adrian Bailey"} } , "tablingMemberConstituency" : {"_value" : "West Bromwich West"} , "tablingMemberPrinted" : [{"_value" : "Mr Adrian Bailey"} ], "uin" : "226526"} , {"_about" : "http://data.parliament.uk/resources/1064472", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1064472/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.<\/p>
<\/p>
NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE\u2019s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-28", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "224025"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-28T11:56:53.813Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the planned timescale is for patients to access Spinraza treatment for muscular atrophy types 2 and 3.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/320", "label" : {"_value" : "Biography information for Mr Adrian Bailey"} } , "tablingMemberConstituency" : {"_value" : "West Bromwich West"} , "tablingMemberPrinted" : [{"_value" : "Mr Adrian Bailey"} ], "uin" : "224024"} , {"_about" : "http://data.parliament.uk/resources/1064473", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1064473/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.<\/p>
<\/p>
NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE\u2019s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-28", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "224024"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-28T11:56:53.86Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress has been made on concluding a managed access treatment agreement for the use of Spinraza for patients with spinal muscular atrophy types 2 and 3.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/320", "label" : {"_value" : "Biography information for Mr Adrian Bailey"} } , "tablingMemberConstituency" : {"_value" : "West Bromwich West"} , "tablingMemberPrinted" : [{"_value" : "Mr Adrian Bailey"} ], "uin" : "224025"} , {"_about" : "http://data.parliament.uk/resources/909541", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/909541/answer", "answerText" : {"_value" : "